Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma

J Eur Acad Dermatol Venereol. 2023 May;37(5):e605-e607. doi: 10.1111/jdv.18871. Epub 2023 Jan 25.

Authors

Lukas Buchacher¹, Georg Richtig², Marie Dernoscheg¹, Erika Richtig¹, Lukas Koch¹

Affiliations

¹ Department of Dermatology, Medical University of Graz, Graz, Austria.
² Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

PMID: 36645848
DOI: 10.1111/jdv.18871

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Drug Tapering
Humans
Melanoma* / pathology
Mitogen-Activated Protein Kinase Kinases / therapeutic use
Protein Kinase Inhibitors / adverse effects
Proto-Oncogene Proteins B-raf
Skin Neoplasms* / pathology

Substances

Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinase Kinases
Protein Kinase Inhibitors
BRAF protein, human